Estimation of the risk of severe TBE in auto-Ab-positive individuals relative to the general population
| Anti-type I IFN auto-Ab (amount of type I IFN neutralized, in plasma diluted 1:10) . | OR (95% CI) . | P value . |
|---|---|---|
| Anti-IFN-α2 (10 ng/ml) | 8.1 (1.8–37.4) | 0.0005565 |
| Anti-IFN-ω (10 ng/ml) | 12.3 (3.0–51.4) | 0.0000022 |
| Anti-IFN-α2 (10 ng/ml) and/or anti-IFN-ω (10 ng/ml) and/or anti-IFN-β (10 ng/ml) | 8.7 (2.3–33.7) | 0.0000053 |
| Anti-IFN-α2 (10 ng/ml) and anti-IFN-ω (10 ng/ml) | 20.8 (4.5–97.4) | 0.0000009 |
| Anti-IFN-α2 (100 pg/ml) | 2.9 (0.6–13.5) | 0.0726972 |
| Anti-IFN-ω (100 pg/ml) | 7.2 (2.1–24.4) | 0.0000002 |
| Anti-IFN-α2 (100 pg/ml) and/or anti-IFN-ω (100 pg/ml) and/or anti-IFN-β (10 ng/ml) | 4.9 (1.5–15.9) | 0.0000113 |
| Anti-IFN-α2 (100 pg/ml) and anti-IFN-ω (100 pg/ml) | 7.4 (1.6–34.3) | 0.0011799 |
| Anti-type I IFN auto-Ab (amount of type I IFN neutralized, in plasma diluted 1:10) . | OR (95% CI) . | P value . |
|---|---|---|
| Anti-IFN-α2 (10 ng/ml) | 8.1 (1.8–37.4) | 0.0005565 |
| Anti-IFN-ω (10 ng/ml) | 12.3 (3.0–51.4) | 0.0000022 |
| Anti-IFN-α2 (10 ng/ml) and/or anti-IFN-ω (10 ng/ml) and/or anti-IFN-β (10 ng/ml) | 8.7 (2.3–33.7) | 0.0000053 |
| Anti-IFN-α2 (10 ng/ml) and anti-IFN-ω (10 ng/ml) | 20.8 (4.5–97.4) | 0.0000009 |
| Anti-IFN-α2 (100 pg/ml) | 2.9 (0.6–13.5) | 0.0726972 |
| Anti-IFN-ω (100 pg/ml) | 7.2 (2.1–24.4) | 0.0000002 |
| Anti-IFN-α2 (100 pg/ml) and/or anti-IFN-ω (100 pg/ml) and/or anti-IFN-β (10 ng/ml) | 4.9 (1.5–15.9) | 0.0000113 |
| Anti-IFN-α2 (100 pg/ml) and anti-IFN-ω (100 pg/ml) | 7.4 (1.6–34.3) | 0.0011799 |